Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model (Q36332037)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17904628 AND SRC:MED&resulttype=core&format=json

8 January 2020

title

Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17904628 AND SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

8 January 2020

main subject

asthma

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17904628 AND SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Ann C Wu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17904628 AND SRC:MED&resulttype=core&format=json

8 January 2020

Karen M Kuntz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17904628 AND SRC:MED&resulttype=core&format=json

8 January 2020

Scott T Weiss

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17904628 AND SRC:MED&resulttype=core&format=json

8 January 2020

Anne L Fuhlbrigge

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17904628 AND SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

English

0 references

publication date

29 September 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17904628 AND SRC:MED&resulttype=core&format=json

The Journal of Allergy and Clinical Immunology

8 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17904628 AND SRC:MED&resulttype=core&format=json

8 January 2020

volume

120

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17904628 AND SRC:MED&resulttype=core&format=json

8 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17904628 AND SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

1146-1152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17904628 AND SRC:MED&resulttype=core&format=json

8 January 2020

cites work

Omalizumab for asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Anti-IgE for chronic asthma in adults and children

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Evaluation of omalizumab from a health plan perspective

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Omalizumab (Xolair) for treatment of asthma.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Steroid resistance in asthma: a major problem requiring novel solutions or a non-issue?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

A comprehensive study of the direct and indirect costs of adult asthma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Systematic overview of cost-utility assessments in oncology

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

An economic evaluation of asthma in the United States

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Economic appraisal of asthma and COPD care: a literature review 1980-1991

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

The Markov process in medical prognosis.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Cost-effectiveness of inhaled steroids in asthma: impact of effect on bone mineral density.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Association between preference-based health-related quality of life and asthma severity.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Omalizumab is effective in the long-term control of severe allergic asthma

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Omalizumab improves asthma-related quality of life in children with allergic asthma

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Costs of asthma according to the degree of severity

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Markov models in medical decision making: a practical guide.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

A randomized trial of A.C.T. (asthma care training) for kids.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3476046

Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index

22 September 2018

1 reference

12 December 2020

Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo

1 reference

12 December 2020

The cost of asthma in the emergency department and hospital

1 reference

12 December 2020

Lack of cost-effectiveness of omalizumab

1 reference

12 December 2020

Has the cost-effectiveness of Xolair (omalizumab) been underestimated?

1 reference

12 December 2020

Omalizumab (Xolair): an anti-IgE antibody for asthma

1 reference

12 December 2020

Cost-effectiveness of including cromolyn sodium in the treatment program for asthma: a retrospective, record-based study

1 reference

12 December 2020

Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia

1 reference

12 December 2020

Relationship between health utility and psychometric health status measures

1 reference

12 December 2020

Cost of asthma illnesses: emergency department visits without admission

1 reference

12 December 2020

Emergency room encounters of pediatric patients with asthma: cost comparisons with other treatment settings

1 reference

12 December 2020

Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2

1 reference

12 December 2020

Cost-effectiveness of interferon alfa in chronic myelogenous leukemia

1 reference

12 December 2020

10.1016/J.JACI.2007.07.055

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17904628 AND SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17904628 AND SRC:MED&resulttype=core&format=json

8 January 2020

PubMed publication ID

17904628

1 reference